NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 57 min ago
Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-372 " Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required)"
Notice NOT-ES-18-003 from the NIH Guide for Grants and Contracts
Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-374 "Mentored Patient-Oriented Research Career Development Award (Parent K23 - Clinical Trial Required)"
Notice NOT-ES-18-004 from the NIH Guide for Grants and Contracts
Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
Funding Opportunity RFA-DA-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.
Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-393 "Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Clinical Trial Required)"
Notice NOT-ES-18-005 from the NIH Guide for Grants and Contracts
Notice to Clarify the Types of Clinical Trials NIBIB Will Support Under PAR-18-206 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
Notice NOT-EB-18-002 from the NIH Guide for Grants and Contracts
Notice of Clarification of NINDS Statement of interest for "Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)"
Notice NOT-NS-18-028 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-117 from the NIH Guide for Grants and Contracts
BRAIN Initiative: Targeted BRAIN Circuits Planning Projects TargetedBCPP (R34 - Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-18-014 from the NIH Guide for Grants and Contracts. This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-18-009). Applications should be exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.
Funding Opportunity RFA-HD-19-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage small businesses to collaborate with scientists and clinicians in the field of gynecologic health to develop, advance, and validate new devices and methods for non-invasive diagnosis of endometriosis, adenomyosis, and/or uterine fibroids. Projects supported will aim to shorten the time to diagnosis, decrease the invasiveness of current techniques, and/or improve accessibility, safety, convenience, and costs of diagnosis.
Funding Opportunity RFA-NS-18-018 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to develop new and improved perturbation technologies suitable for controlling specified cell types and circuits to modulate function in the central nervous system. This FOA seeks applications to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation. Development of new technologies and therapies, as well as of disease models are outside the scope of this FOA. However, activities related to combining multiple recording modalities are allowed. As part of this program, investigators will be required to participate in a consortium to develop standards and model systems for the evaluation of current and next generation neuromodulation technologies.
Notice of National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Drug Abuse (NIDA) Interest in Blueprint Neurotherapeutic Network Applications Directed at Small Molecule Non-Addictive Pain Therapies
Notice NOT-NS-18-027 from the NIH Guide for Grants and Contracts
Notice NOT-FD-18-006 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-504 from the NIH Guide for Grants and Contracts. The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution.
Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-370 "Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)"
Notice NOT-ES-18-002 from the NIH Guide for Grants and Contracts
Interaction of HIV Infection and Alcohol Abuse on Central Nervous System Morbidity Limited Competition (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AA-18-008 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites a limited competing renewal of a U01 project to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse. This project has recruited and longitudinally tracked a large cohort of individuals with HIV infection, or alcohol abuse, or the comorbid condition. As members of this cohort are growing older and living well longer due to antiretroviral medications, this project is well suited to address several questions of current interest in the HIV-AIDS research community. These questions include the effects of coinfection with the Hepatitis C virus, the involvement of peripheral neuropathy as a factor in frailty, potential neurotoxic effects of antiretroviral medications, and interactive effects with advancing age on sensory and motor functioning.
Notice of NIAMS' Participation in PA-18-398 "NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed"
Notice NOT-AR-18-012 from the NIH Guide for Grants and Contracts
Notice of Clarification on Award Project Period for PAR-17-003 "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)"
Notice NOT-CA-18-026 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-119 from the NIH Guide for Grants and Contracts
NIBIB Notice to Clarify the Types of Clinical Trials NIBIB Will Support Under PAR-18-205, NIBIB Biomedical Technology Resource Centers (P41 Clinical Trial Optional)
Notice NOT-EB-18-001 from the NIH Guide for Grants and Contracts
Additional Short-Term Administrative Relief to Institutions Impacted by Hurricanes Harvey, Irma, and Maria
Notice NOT-OD-18-114 from the NIH Guide for Grants and Contracts
NIH Funding Opportunities
- End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)
- End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)
- Human Subjects Mechanistic and Minimal Risk Studies (R21 Clinical Trial Optional)
- NIBIB Exploratory/Developmental Research Grant Program (R21) (Clinical Trial Optional)
- Sleep disorders and circadian clock disruption in Alzheimers disease and other dementias of aging (R01 Clinical Trial Not Allowed)